RBC Capital Reiterates Outperform Rating on Ligand Pharma (LGND), Investor Day Preview
Tweet Send to a Friend
RBC Capital analyst Douglas Miehm reiterated an Outperform rating and $234.00 price target on Ligand Pharma (NASDAQ: LGND).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
